美国商用葡萄糖生物感测器市场规模、份额、趋势分析报告：按应用、主要企业、竞争分析、细分预测，2025-2030 年

美国OTC葡萄糖生物感测器市场趋势：

预计 2024 年美国非处方 (OTC) 葡萄糖生物感测器市场规模将达到 1.053 亿美元，2025 年至 2030 年复合年增长率为 11.5%。

推动市场成长的因素包括糖尿病和糖尿病前期盛行率不断上升、预防性医疗保健的转变以及运动员越来越多地采用葡萄糖生物感测器等。此外，这个年龄层的人更容易患糖尿病等慢性疾病，从而增加了对葡萄糖生物感测器等有效解决方案的需求。

人口老化、肥胖和不健康的生活方式导致糖尿病盛行率不断上升，是推动美国非处方（OTC）葡萄糖生物感测器产业成长的因素之一。肥胖是导致糖尿病的一个主要因素。根据哥伦比亚广播公司 2024 年 9 月发布的新闻报道，到 2020 年，大约 30% 的成年人将被归类为肥胖，这意味着他们的体重指数 (BMI) 为 30 或更高。此外，疾病预防控制中心报告称，到 2020 年，成人肥胖率将上升至 41.9%。目前，根据2021-2023年的调查资料，CDC估计40.3%的成年人有肥胖问题。除了肥胖之外，糖尿病在世界各地也变得越来越普遍。国际糖尿病联盟（IDF）估计，2021年将有5.37亿成年人（20-79岁）患有糖尿病，预计2040年将上升到6.42亿。 IDF报告也指出，全球糖尿病盛行率呈上升趋势，中低收入国家的增幅最大。

糖尿病是一个普遍的健康问题，影响着美国数百万人。据美国疾病管制与预防中心 (CDC) 称，截至 2024 年，美国人口的 11.6%（各年龄层约 3,840 万人）将被诊断出患有糖尿病。 18岁以上成年人的盛行率更高，达14.7%，即3810万人受到影响。大约有 870 万名患有糖尿病的成年人不知道或未报告自己患有糖尿病，占糖尿病成年人总数的 22.8%，占美国成年人总数的 3.4%。罹患糖尿病的风险随着年龄的增长而增加，65岁及以上人口的比例最高，为29.2%。这些统计数据凸显了糖尿病对美国人口的重大影响。

此外，向预防性医疗保健的转变也促进了美国非处方（OTC）葡萄糖生物感测器产业的发展。日益增强的认知、政府措施和技术进步正在推动消费者优先考虑健康管理，以避免糖尿病等慢性疾病。预防性医疗保健强调早期检测和持续监测，这推动了对方便、易于使用的血糖监测设备的需求。

Stelo 和 Lingo 等非处方葡萄糖生物感测器为人们提供了一种方便的、非处方笺的居家血糖值监测选择。这些设备设计紧凑，易于使用，并提供无缝的智慧型手机集成，以实现即时追踪和资料分析。 Stelo 和 Lingo 支援主动健康管理，使用户能够及早发现血糖水平的变化并及时采取行动，促进预防性糖尿病护理。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3美国。

• 市场介绍/电网展望
• 市场规模和成长前景
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 美国非处方 (OTC) 葡萄糖生物感测器市场分析工具
  • 波特的分析
  • PESTEL 分析

美国4 章。

• 细分仪表板
• 美国非处方 (OTC) 葡萄糖生物感测器市场：最终用途变化分析，2024 年和 2030 年
• 医疗保健专业办公室 (HCP)
• 专科门诊
• 居家护理

第五章 竞争格局

• 主要市场参与企业的近期趋势及影响分析
• 公司分类
• 公司热图分析
• 公司简介
  • DexCom, Inc.
  • Abbott

U.S. OTC Glucose Biosensors Market Trends:

The U.S. over-the-counter glucose biosensors market size was estimated at USD 105.3 million in 2024 and is anticipated to exhibit a CAGR of 11.5% from 2025 to 2030. This growth is attributed to the increasing prevalence of diabetes and prediabetes, the shift towards preventive healthcare, and the increased adoption of glucose biosensors by athletes are some of the major factors driving market growth. Moreover, the aging population of the country further contributes to this growth as this age group is significantly vulnerable to chronic diseases such as diabetes, which increases the demand for effective solutions such as glucose biosensors.

The increase in the prevalence of diabetes due to aging, obesity, and unhealthy lifestyle is one of the factors contributing to the growth of the U.S. over-the-counter (OTC) glucose biosensors industry. Obesity is a major factor leading to diabetes. According to CBS News published in September 2024, approximately 30% of adults were classified as obese, with a body mass index (BMI) of 30 or higher in 2020. Furthermore, the CDC reported an increase in the adult obesity rate to 41.9% by 2020. Currently, based on survey data from 2021 to 2023, the CDC estimates that 40.3% of adults are obese. In addition to obesity, diabetes is becoming increasingly prevalent globally. The International Diabetes Federation (IDF) estimates that there were 537 million adults (aged 20-79) living with diabetes in 2021, and this number is expected to increase to 642 million by 2040. The IDF also reports that the prevalence of diabetes is growing globally, with the highest increase witnessed in low- and middle-income countries.

In the U.S., diabetes is a widespread health issue affecting millions of people. According to the CDC, as of 2024, 11.6% of the entire U.S. population-about 38.4 million people of all ages-has been diagnosed with diabetes. The percentage of adults aged 18 or older is even higher, with 14.7% or 38.1 million people affected. Around 8.7 million adults with diabetes were unaware of their condition or did not report it, representing 22.8% of all adults with diabetes and 3.4% of all U.S. adults. The risk of diabetes increases with age, with the percentage of adults with diabetes peaking at 29.2% among those aged 65 or above. These statistics highlight the significant impact that diabetes has on the U.S. population.

Moreover, the shift towards preventive healthcare is also contributing to the growth of the U.S. over-the-counter (OTC) glucose biosensors industry. Consumers increasingly prioritize health management to avoid chronic diseases such as diabetes, driven by rising awareness, government initiatives, and technological advancements. Preventive healthcare emphasizes early detection and continuous monitoring, fueling demand for accessible and user-friendly glucose monitoring devices.

OTC glucose biosensors such as Stelo and Lingo provide individuals with convenient, non-prescription options to monitor blood glucose levels at home. These devices offer ease of use with compact designs and seamless smartphone integration for real-time tracking and data analysis. Stelo and Lingo support proactive health management, enabling users to detect early changes in their glucose levels and take timely action, promoting a preventive approach to diabetes care.

U.S. Over-the-Counter Glucose Biosensors Market Report Segmentation

This report forecasts revenue growth at country levels and analyzes the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. over-the-counter glucose biosensors market report based on end use:

• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Healthcare Professional Offices (HCPs)
• Specialty Clinics
• Homecare

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Over the Counter (OTC) glucose biosensors Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Increasing prevalence of diabetes and prediabetes
    • 3.3.1.2. Shift towards preventive healthcare
    • 3.3.1.3. Increased adoption of glucose biosensors by athletes
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Lack of coverage under insurance plans
    • 3.3.2.2. Limitations in OTC biosensors functionality
    • 3.3.2.3. Regulatory challenges
• 3.4. U.S. Over-the-Counter (OTC) Glucose Biosensors Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. U.S. Over-the-Counter (OTC) Glucose Biosensors Market: End Use Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Over-the-Counter (OTC) Glucose Biosensors Market: End Use Movement Analysis, USD Million, 2024 & 2030
• 4.3. Healthcare Professional Offices (HCPs)
  • 4.3.1. Healthcare Professional Offices (HCPs) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Specialty Clinics
  • 4.4.1. Specialty Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Homecare
  • 4.5.1. Homecare Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Competitive Landscape

• 5.1. Recent Developments & Impact Analysis by Key Market Participants
• 5.2. Company Categorization
• 5.3. Company Heat Map Analysis
• 5.4. Company Profiles
  • 5.4.1. DexCom, Inc.
    • 5.4.1.1. Participant's Overview
    • 5.4.1.2. Financial Performance
    • 5.4.1.3. Product Benchmarking
    • 5.4.1.4. Recent Developments/ Strategic Initiatives
  • 5.4.2. Abbott
    • 5.4.2.1. Participant's Overview
    • 5.4.2.2. Financial Performance
    • 5.4.2.3. Product Benchmarking
    • 5.4.2.4. Recent Developments/ Strategic Initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 U.S. Over-the-Counter (OTC) glucose biosensors market by end use, 2018 - 2030 (USD Million)
• Table 4 Participant's overview
• Table 5 Financial performance
• Table 6 Key companies undergoing expansions
• Table 7 Key companies undergoing acquisitions
• Table 8 Key companies undergoing collaborations
• Table 9 Key companies launching new products
• Table 10 Key companies undergoing partnerships
• Table 11 Key companies undertaking other strategies

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Market summary, 2024 (USD Million)
• Fig. 9 Market segmentation & scope
• Fig. 10 Market driver impact
• Fig. 11 Market restraint impact
• Fig. 12 Porter's analysis
• Fig. 13 SWOT analysis
• Fig. 14 U.S. Over-the-Counter (OTC) glucose biosensors market: End use outlook and key takeaways
• Fig. 15 U.S. Over-the-Counter (OTC) glucose biosensors market: End use movement analysis
• Fig. 16 Healthcare Professional Offices (HCPs) market, 2018 - 2030 (USD Million)
• Fig. 17 Specialty clinics market, 2018 - 2030 (USD Million)
• Fig. 18 Homecare market, 2018 - 2030 (USD Million)
• Fig. 19 Heat map analysis
• Fig. 20 Market participant categorization
• Fig. 21 U.S. Over-the-Counter (OTC) glucose biosensors market share analysis, 2024
• Fig. 22 Strategy framework